Natera develops cell-free DNA (cfDNA) testing technology for genetic diagnostics across oncology, women's health, and organ health. The company operates ISO 13485-certified and CAP-accredited laboratories in Austin, Texas and San Carlos, California, serving patients and healthcare providers worldwide.
The company's platform combines molecular biology techniques with advanced bioinformatics and artificial intelligence to detect genetic material at the single-molecule level in blood samples. Its product portfolio includes Panorama™ for prenatal screening, Signatera™ for personalized cancer detection, and Prospera™ for transplant monitoring. Natera's work is supported by more than 300 peer-reviewed publications.
The company aims to integrate personalized genetic testing and diagnostics into standard clinical care, focusing on enabling earlier and more targeted medical interventions.
